Peregrine Pharmaceuticals | PPHM - Capitaux D'Emprunt



Capitaux D'Emprunt Changement Date
Agenus USD 23.6M 448K 2025-09
Amgen USD 50B 2.43B 2025-12
AstraZeneca USD 26.14B 19.58B 2025-12
BioCryst Pharmaceuticals USD 194.37M 48.43M 2025-09
Bristol-Myers Squibb USD 42.85B 1.62B 2025-12
Eli Lilly USD 40.87B 5.6M 2025-12
GlaxoSmithKline GBP 14.71B 186M 2025-12
Intrexon USD 0 198.67M 2024-06
Karyopharm Therapeutics USD -0.93 0.67 2024-12
MacroGenics USD 70.26M 4K 2025-09
MannKind USD 548.44M 244.79M 2025-12
Merck USD 39.97B 6B 2025-09
Minerva Neurosciences USD 0 86.58M 2024-09
Novartis USD 24.24B 174M 2025-09
Novavax USD 223.63M 187K 2024-09
Repligen USD 542.21M 4.29M 2025-12
Roche Holding CHF 27.43B 966M 2025-12
Xencor USD 76.48M 11.29M 2025-12